Powered By
Large scale study out of UK suggests 94% after 5years with no disease progression and 55% of those had NED in their bone marrow. I am curious how accurate this is. https://ashpublications.org/blood/article/144/S...
I have now reached UMRD and will continue the Venetoclax for a year to ensure a durable remission.
I have SLL and have been on Ibrutinib/Venetaclax for 5 months. I also have the unmutated IGVH gene. My oncologist recommended the Ritux infusions, but I was afraid of the side effects and refused it, probably a bad decision. I’m very anemic and have been getting EPO shots, so far no help. Becoming more fatigued
The only side effects from the Rituxan for me was a mild headache.
I have taken Ibrutinib and Venetoclax together. I did not do it as long as the Flair study in Britain. I had been on Ibrutinib for 7 years and was showing resistance this winter. In May I added the Rituxan infusions and in June I started the Venetoclax ramp up. 5 weeks later I stopped the Ibrutinib. Actually I stopped 3 days shy as the diarrhea from the full strength of both drugs was too much. I have had almost no side effects from the Venetoclax as a result of this regimen. My white cell count was 11,000 after the first infusion. Now I am at4.7. It’s amazing. I also have unmutated IGVH . I was first diagnosed in 2010.
While the specific UK study numbers can't be directly confirmed from available data, we do know that both ibrutinib and venetoclax are effective treatments for CLL/SLL. Ibrutinib alone has shown impressive results, reducing disease progression risk by 63% compared to standard treatments in first-round therapy.
Venetoclax Show Full Answer
Join
Your Privacy Choices
